source
- Novo signs $1.4 billion deal with Orbis Medicines to develop oral macrocycle cardiometabolic drugsNovo, which recently rebranded from Novo Nordisk, announced a partnership with Copenhagen‑based Orbis Medicines. The agreement could provide up to $1.4 billion in upfront payments and milestone pay…
- Novartis halts ALS drug VHB937 after phase 2 trial fails to meet endpointsNovartis announced it is stopping development of its ALS candidate VHB937 after the phase 2 Astrals trial did not meet its primary or secondary endpoints. The study enrolled 251 patients with earl…